Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis

Annals of Pharmacotherapy

Volumn 44, Issue 3, 2010, Pages 582-586

  Ray, Leslie ^a,b   Levasseur, Kimberly ^a   Nicolau, David P ^c   Scheetz, Marc H ^a,d  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c HARTFORD HOSPITAL   (United States)

^d MIDWESTERN UNIVERSITY   (United States)

Author keywords

Cerebral spinal fluid; Cerebritis; Concentration; Meningitis; Tigecycline

Indexed keywords

ACICLOVIR; AMIKACIN; BILIRUBIN; CIPROFLOXACIN; COLISTIN; GLUCOSE; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN; RIFAMPICIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER BAUMANNII CEREBRITIS; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CAROTID ARTERY INJURY; CASE REPORT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONFUSION; CONTINUOUS INFUSION; CRANIECTOMY; DEBRIDEMENT; DEEP VEIN THROMBOSIS; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENCEPHALITIS; ERYTHROCYTE; FEMALE; FEVER; HEADACHE; HUMAN; INTERNAL CAROTID ARTERY; LETHARGY; LEUKOCYTE; LUMBAR PUNCTURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIAL IDENTIFICATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NECK PAIN; PHOTOPHOBIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REHABILITATION CARE; RIGIDITY; SINGLE DRUG DOSE; STROKE; URINARY TRACT INFECTION; VEIN PUNCTURE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENCEPHALITIS; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TREATMENT OUTCOME;

EID: 77749314298     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M480     Document Type: Article

References (22)

1. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358:1271-81.
2. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009;9:245-55.
3. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005;41:848-54.
4. Qi C, Malczynski M, Parker M, Scheetz MH. Characterization of genetic diversity of carbapenem-resistant Acinetobacter baumannii clinical strains collected from 2004 to 2007. J Clin Microbiol 2008;46:1106-9.
5. Scheetz MH, Qi C, Warren JR, et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:1621-6.
6. Product information. Tygacil (tigecycline). Philadelphia, PA: Wyeth Pharmaceuticals Inc., March 2009.
7. Clinical and Laboratory Standards Institute performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19 (ISBN 1-56238-690-5). Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
8. Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O'Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005;49:3903-9.
9. Li C, Sutherland CA, Nightingale CH, Nicolau DP. Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2004;811:225-9.
10. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004;64:63-88.
11. Smilack JD, Wilson WR, Cockerill FR 3rd. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clin Proc 1991;66:1270-80.
12. Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother 1985;28:347-8.
13. Allen JC. Minocycline. Ann Intern Med 1976;85:482-7.
14. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221-9.
15. Dandache P, Nicolau DP, Sakoulas G. Tigecyline for the treatment of multidrug-resistant Klebsiella pneumoniae meningitis. Infect Dis Clin Pract 2009;17:66-8.
16. Clinical pharmacology and biopharmaceutics review(s). Wyeth Pharmaceuticals. New Drug Application no.: 21-821. Center for Drug Evaluation and Research, 2005. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2005/21- 821-Tygacil-BioPharmr.pdf (accessed 2009 Jul 29).
17. Chen JL, Orsini J, Killu C. Poor central nervous system penetration of tigecycline in a patient with sepsis and ventriculitis caused by multidrug-resistant Klebsiella pneumoniae. J Pharm Technol 2007;23:344-8.
18. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-9.
19. Wadi JA, Al Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann Saudi Med 2007;27:456-8.
20. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002;49(suppl 1):21-30.
21. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-8.
22. Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53:2756-61.